2024
Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments
Lambert C, Hussain T, Peters J, Longbrake E. Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments. Multiple Sclerosis And Related Disorders 2024, 94: 106236. PMID: 39755026, PMCID: PMC11869388, DOI: 10.1016/j.msard.2024.106236.Peer-Reviewed Original ResearchMeSH KeywordsAdultFemaleHumansImmunologic FactorsImmunomodulating AgentsInfectionsMaleMiddle AgedMultiple SclerosisNatalizumabRetrospective StudiesConceptsCharlson Comorbidity IndexAnti-CD20 medicationsDisease-modifying treatmentsDMT useS1P modulatorsImmunomodulatory treatmentImmune cellsSevere infectionsMultiple sclerosisLong-term immunomodulatory treatmentReal-life practice patternsTreatment durationInfection rateSelection of patientsClinical selection of patientsDeplete immune cellsObservational cohort studyBody mass indexSevere infection rateAnalyzed medical recordsIncreased infection riskInfection riskDisease modifying therapiesMultiple sclerosis patientsImmune subsets
2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman L, Longbrake E, Coyle P, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 2022, 36: 1285-1299. PMID: 36350491, PMCID: PMC9645316, DOI: 10.1007/s40263-022-00965-7.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabHumansImmunologic FactorsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingNatalizumabConceptsRelapsing-remitting multiple sclerosisHigh-efficacy therapiesMultiple sclerosisClinical benefitEarly treatmentRecent international consensus guidelinesLong-term clinical outcomesAvailable treatment optionsInternational consensus guidelinesTreatment-naïve individualsMechanism of actionDMT optionsMS careDisease courseClinical outcomesConsensus guidelinesTherapy optionsTreatment optionsNeurological damageTreatment strategiesEscalation approachClinical practiceUS FoodDrug AdministrationPatients
2021
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease
Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease. Neurology Neuroimmunology & Neuroinflammation 2021, 8: e1046. PMID: 34341094, PMCID: PMC8362350, DOI: 10.1212/nxi.0000000000001046.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionHospitalization ratesRisk factorsSevere coronavirus disease 2019 (COVID-19) infectionDisease-modifying therapy useCoronavirus disease 2019 (COVID-19) infectionStepwise multivariate logistic regressionCNS Demyelinating DiseaseNausea/vomitingAbsolute lymphocyte countIndependent risk factorNumber of comorbiditiesDisease 2019 infectionPatient risk factorsRisk of hospitalizationCOVID-19 cohortDisease-modifying therapiesCase fatality rateMultivariate logistic regressionCOVID-19 registryFisher's exact testDemyelinating diseaseClinical characteristicsLymphocyte countNeurologic symptomsInfluence of immunomodulatory drugs on the gut microbiota
Cohen I, Ruff WE, Longbrake EE. Influence of immunomodulatory drugs on the gut microbiota. Translational Research 2021, 233: 144-161. PMID: 33515779, PMCID: PMC8184576, DOI: 10.1016/j.trsl.2021.01.009.Peer-Reviewed Original ResearchMeSH KeywordsAdaptive ImmunityCell ProliferationCytokinesFemaleGastrointestinal MicrobiomeHost Microbial InteractionsHumansImmune Checkpoint InhibitorsImmunity, InnateImmunity, MucosalImmunologic FactorsImmunomodulationLymphocytesMaleModels, ImmunologicalSex FactorsTranslational Research, BiomedicalConceptsImmune checkpoint inhibitorsGut microbiotaCheckpoint inhibitorsAutoimmune diseasesMainstay of treatmentType of immunotherapyInflammatory cytokine inhibitorComprehensive literature searchMechanism of actionImmunomodulatory medicationsDrug-induced shiftImmunomodulatory drugsCytokine inhibitorsImmunotherapy effectImmune cellsClinical significanceImmune responseMost immunotherapiesCommensal microbesDrug efficacyImmunotherapyLiterature searchAntiproliferative drugsMedicationsMicrobiota
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply